ATE509096T1 - Von sparc abgeleitetes krebsabstossungsantigenpeptid und pharmazeutikum, das dieses enthält - Google Patents

Von sparc abgeleitetes krebsabstossungsantigenpeptid und pharmazeutikum, das dieses enthält

Info

Publication number
ATE509096T1
ATE509096T1 AT07745372T AT07745372T ATE509096T1 AT E509096 T1 ATE509096 T1 AT E509096T1 AT 07745372 T AT07745372 T AT 07745372T AT 07745372 T AT07745372 T AT 07745372T AT E509096 T1 ATE509096 T1 AT E509096T1
Authority
AT
Austria
Prior art keywords
sparc
peptide
cells
acid sequence
amino acid
Prior art date
Application number
AT07745372T
Other languages
English (en)
Inventor
Yasuharu Nishimura
Yoshiaki Ikuta
Shuichi Nakatsuru
Original Assignee
Onco Therapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onco Therapy Science Inc filed Critical Onco Therapy Science Inc
Application granted granted Critical
Publication of ATE509096T1 publication Critical patent/ATE509096T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT07745372T 2006-06-16 2007-06-15 Von sparc abgeleitetes krebsabstossungsantigenpeptid und pharmazeutikum, das dieses enthält ATE509096T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006167724 2006-06-16
PCT/JP2007/062117 WO2007145318A1 (ja) 2006-06-16 2007-06-15 Sparc由来の癌拒絶抗原ペプチド及びこれを含む医薬

Publications (1)

Publication Number Publication Date
ATE509096T1 true ATE509096T1 (de) 2011-05-15

Family

ID=38831831

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07745372T ATE509096T1 (de) 2006-06-16 2007-06-15 Von sparc abgeleitetes krebsabstossungsantigenpeptid und pharmazeutikum, das dieses enthält

Country Status (14)

Country Link
US (3) US8053557B2 (de)
EP (1) EP2030984B1 (de)
JP (1) JP5150849B2 (de)
KR (1) KR101408173B1 (de)
CN (3) CN101472943B (de)
AT (1) ATE509096T1 (de)
AU (1) AU2007259667B2 (de)
BR (1) BRPI0713731B8 (de)
CA (1) CA2655361C (de)
ES (1) ES2365077T3 (de)
IL (1) IL195831A (de)
MX (1) MX2008015939A (de)
RU (1) RU2451521C2 (de)
WO (1) WO2007145318A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103242428B (zh) 2005-08-09 2015-04-15 肿瘤疗法.科学股份有限公司 用于hla-a2阳性人群的来自磷脂酰肌醇蛋白聚糖-3 (gpc3)的癌症排斥抗原肽以及含有该肽的药物
RU2451521C2 (ru) 2006-06-16 2012-05-27 Онкотерапи Сайенс, Инк. Sparc-производные антигенные пептиды отторжения опухоли и лекарственные средства, содержащие их
TWI615403B (zh) * 2007-02-21 2018-02-21 腫瘤療法 科學股份有限公司 表現腫瘤相關抗原之癌症的胜肽疫苗
TWI580431B (zh) 2008-08-19 2017-05-01 腫瘤療法 科學股份有限公司 Ｈｉｇ２與ｕｒｌｃ１０抗原決定位胜肽以及含此胜肽之疫苗
WO2010065954A2 (en) 2008-12-05 2010-06-10 Abraxis Bioscience, Llc Sparc binding peptides and uses thereof
TWI507204B (zh) * 2009-05-26 2015-11-11 Oncotherapy Science Inc Ｃｄｃ４５ｌ胜肽與含此胜肽之疫苗
JP2013505268A (ja) * 2009-09-18 2013-02-14 アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー 癌の治療におけるｓｐａｒｃ微小環境シグネチャの使用
KR20130010477A (ko) * 2010-03-11 2013-01-28 아브락시스 바이오사이언스, 엘엘씨 Ｓｐａｒｃ 혈관형성 영역과 사용방법
CN103002905A (zh) 2010-06-03 2013-03-27 阿布拉西斯生物科学有限责任公司 Sparc微环境标签在癌症治疗中的应用
RU2634862C2 (ru) 2011-05-19 2017-11-07 Торэй Индастриз, Инк. Агент, индуцирующий иммунитет
WO2019138944A1 (ja) * 2018-01-09 2019-07-18 学校法人藤田学園 細胞殺傷剤
CN111788214B (zh) * 2018-02-15 2021-06-22 国立大学法人旭川医科大学 癌症抗原肽
JP7273421B2 (ja) 2018-02-21 2023-05-15 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0659439B1 (de) * 1993-12-24 2001-10-24 MERCK PATENT GmbH Immunokonjugate
JP2000023673A (ja) * 1998-07-13 2000-01-25 Ajinomoto Co Inc ヒト胃癌抗原遺伝子および胃癌抗原蛋白質
AU2001266787A1 (en) * 2000-06-07 2002-01-08 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US7074901B2 (en) * 2001-05-25 2006-07-11 Serono Genetics Institute S.A. Isolated human vCOL16A1 polypeptide and fragments thereof
WO2004020624A1 (ja) * 2002-08-30 2004-03-11 Kumamoto Technology & Industry Foundation 癌抗原及びその利用
AU2003263607A1 (en) * 2002-10-25 2004-05-13 Japan As Represented By The President Of The University Of Tokyo Method for diagnosing diffuse-type gastric cancer
JP2004303688A (ja) 2003-04-01 2004-10-28 Matsushita Electric Works Ltd 放電灯点灯装置
JP4336898B2 (ja) * 2003-10-29 2009-09-30 財団法人くまもとテクノ産業財団 悪性黒色腫（メラノーマ）の診断剤
WO2006043362A1 (ja) * 2004-10-19 2006-04-27 Kumamoto University 悪性黒色腫（メラノーマ）の新規な診断キット
CN103242428B (zh) * 2005-08-09 2015-04-15 肿瘤疗法.科学股份有限公司 用于hla-a2阳性人群的来自磷脂酰肌醇蛋白聚糖-3 (gpc3)的癌症排斥抗原肽以及含有该肽的药物
RU2451521C2 (ru) 2006-06-16 2012-05-27 Онкотерапи Сайенс, Инк. Sparc-производные антигенные пептиды отторжения опухоли и лекарственные средства, содержащие их

Also Published As

Publication number Publication date
CN105418751A (zh) 2016-03-23
ES2365077T3 (es) 2011-09-21
KR101408173B1 (ko) 2014-06-16
BRPI0713731B1 (pt) 2019-09-24
US9120842B2 (en) 2015-09-01
CN101472943A (zh) 2009-07-01
US8470968B2 (en) 2013-06-25
EP2030984B1 (de) 2011-05-11
CN103435683A (zh) 2013-12-11
AU2007259667B2 (en) 2012-06-14
HK1128924A1 (en) 2009-11-13
US20130288363A1 (en) 2013-10-31
KR20090038873A (ko) 2009-04-21
CA2655361C (en) 2014-10-07
IL195831A (en) 2012-05-31
CN103435683B (zh) 2016-02-03
WO2007145318A1 (ja) 2007-12-21
BRPI0713731A2 (pt) 2012-10-30
RU2451521C2 (ru) 2012-05-27
RU2009101191A (ru) 2010-08-10
CN101472943B (zh) 2013-07-17
US20120115221A1 (en) 2012-05-10
BRPI0713731B8 (pt) 2021-05-25
CA2655361A1 (en) 2007-12-21
EP2030984A4 (de) 2009-08-26
IL195831A0 (en) 2011-08-01
JPWO2007145318A1 (ja) 2009-11-12
CN105418751B (zh) 2019-03-05
JP5150849B2 (ja) 2013-02-27
AU2007259667A1 (en) 2007-12-21
EP2030984A1 (de) 2009-03-04
US20100152421A1 (en) 2010-06-17
US8053557B2 (en) 2011-11-08
MX2008015939A (es) 2009-02-11

Similar Documents

Publication Publication Date Title
ATE509096T1 (de) Von sparc abgeleitetes krebsabstossungsantigenpeptid und pharmazeutikum, das dieses enthält
TWI417103B (zh) Ｈｌａ-ａ＊１１０１限制性ｗｔ１胜肽及含有該限制性胜肽之醫藥組成物
RU2435782C2 (ru) Hla-a*3303-рестриктированный пептид wt1 и содержащая его фармацевтическая композиция
JP2021168652A (ja) Ｎｓｃｌｃをはじめとする肺がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチド組み合わせ
EP2189471A4 (de) Foxm1-peptid und arzneimittel damit
IN2012DN02981A (de)
DE60327786D1 (de) Kdr-peptide und diese enthaltende impfstoffe
FI3256579T3 (fi) Kysteiiniproteaasi
WO2006090810A3 (en) Peptide vaccines for lung cancers expressing ttk, urlc10 or koc1 polypeptides
EA200601738A1 (ru) Модифицированные белки буганины, цитотоксины и способы их применения
CY1112867T1 (el) Πεπτιδια επιτοπων που προερχονται απο τον υποδοχεα 1 του αγγειακου ενδοθηλιακου αυξητικου παραγοντα και εμβολια περιεχοντας αυτα τα πεπτιδια
RU2008109015A (ru) Глипикан-3 (gpc3)-производные антигенные пептиды, отторгающие опухоли, используемые для нla-a2-положительных пациентов, и фармацевтическая продукция, включающая их
MX2009007261A (es) Vacuna de peptido foxp3.
US10919940B2 (en) Cyclic peptide for treating cancer
EP1536006A4 (de) Krebsantigene und deren nutzung
ES2882827T3 (es) Péptido inductor de inmunidad derivado de HSP70
BR112012025567A2 (pt) peptídeos de cdca5 e vacinas que incluem os mesmos
DE60143818D1 (de) Alpha-fetoprotein-peptide und ihre verwendung
MX2010005816A (es) Epítopos de péptido de stat3.
Vernieri et al. An optimized Fmoc synthesis of human defensin 5
US11142561B2 (en) B1SP fusion protein therapeutics, methods, and uses
WO2005123760A3 (en) Treating cancer
MX2012006770A (es) Peptidos tmem22 y vacunas que incluyen los mismos.
EA201291004A1 (ru) Пептиды ect2 и включающие их вакцины
CN106589062A (zh) 靶向Grb2蛋白的抗肿瘤共价多肽抑制剂及其制备方法和应用

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2030984

Country of ref document: EP